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Summary
Pilocarpine has been used in
the treatment of xerostomia;
however, it is still uncertain
whether it has a preventive
effect on radiation-induced
xerostomia. Our systematic
review and meta-analysis
demonstrated that concomi-
tant administration of pilo-
carpine during radiation
could increase unstimulated
salivary ﬂow rate and reduce
clinician-rated xerostomia
grade. It may also relieve
patients’ xerostomia at
6 months, and possibly at
Purpose: To evaluate the efﬁcacy of concomitant administration of pilocarpine on
radiation-induced xerostomia in patients with head and neck cancers.
Methods and Materials: The PubMed, Web of Science, Cochrane Library, and Clin-
icalTrials were searched to identify randomized, controlled trials studying the effect of
concomitant administration of pilocarpine for radiation-induced xerostomia. Included
trials were systematically reviewed, and quantiﬁable outcomes were pooled for meta-
analysis. Outcomes of interest included salivary ﬂow, clinician-rated xerostomia grade,
patient-reported xerostomia scoring, quality of life, and adverse effects.
Results: Six prospective, randomized, controlled trials in 8 articles were included in
this systematic review. The total number of patients was 369 in the pilocarpine group
and 367 in the control group. Concomitant administration of pilocarpine during radi-
ation could increase the unstimulated salivary ﬂow rate in a period of 3-6 months after
treatment, and also reduce the clinician-rated xerostomia grade. Patient-reported xer-
ostomia was not signiﬁcantly impacted by pilocarpine in the initial 3 months but was
superior at 6 month. No signiﬁcant difference of stimulated salivary ﬂow rate could be
conﬁrmed between the 2 arms. Adverse effects of pilocarpine were mild and tolerable.
Conclusions: The concomitant administration of pilocarpine during radiation in-
creases unstimulated salivary ﬂow rate and reduces clinician-rated xerostomia grade
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12 months. However, it had
no effects on stimulated
salivary ﬂow rate.
after radiation. It also relieves patients’ xerostomia at 6 months and possibly at
12 months. However, pilocarpine has no effect on stimulated salivary ﬂow rate.
 2015 Elsevier Inc. All rights reserved.
Introduction
Radiation therapy plays an important role in the multidis-
ciplinary therapy of head and neck cancer, either as an
adjunctive method or as the main treatment regimen.
Among the acute and chronic side effects of radiation
therapy, xerostomia is one of the most common complaints.
Xerostomia is the subjective dryness of mouth, which may
be associated with reduced salivary ﬂow or changes in the
composition of saliva (1, 2). Individuals with xerostomia
often complain of difﬁculties in speech and swallowing,
impairment of taste, and deterioration of dental hygiene,
greatly impairing patients’ quality of life (QoL) (3).
Some treatment options have been put forward to relieve
radiation-induced xerostomia, including salivary substitutes
and sialagogic agents (4). Pilocarpine, a cholinergic
agonist, stimulates saliva production and has been
approved by the US Food and Drug Administration for the
treatment of xerostomia. Preventive regimens are more
promising, including submandibular gland transfer before
radiation therapy, and parotid gland sparing techniques
with 3-dimensional conformal or intensity modulated ra-
diation therapy (IMRT) (5, 6). However, only selected
candidates are suitable for submandibular gland transfer.
Studies have conﬁrmed the signiﬁcant role of IMRT in
preventing xerostomia and maintaining normal oral func-
tions (7-11). Even with IMRT, however, the salivary glands
may still overlap the planning target volume partially,
resulting in some degree of salivary gland impairment and
xerostomia (8, 12, 13).
An early clinical trial revealed that the concomitant
administration of pilocarpine during radiation therapy was
effective in preventing radiation-induced xerostomia in
patients with head and neck cancers (14). However, its
exact efﬁcacy is under investigation, and to date, no re-
ported trial has been convincing enough to validate the
efﬁcacy of pilocarpine for the prevention of xerostomia.
Compelling evidence is needed before concomitant pilo-
carpine can be recommended for routine use. Therefore, we
aimed to conduct a systematic review and meta-analysis to
evaluate the efﬁcacy of concomitant administration of
pilocarpine on radiation-induced xerostomia in patients
with head and neck cancers.
Methods and Materials
Search strategy
We performed a comprehensive search in PubMed, Web of
Science, Cochrane Library, and ClinicalTrials for relevant
articles using different combinations of the following key
words: “pilocarpine” or “salagen” and “radiation” or
“radiotherapy” and “xerostomia” or “dry mouth” or
“hyposalivation.” All articles published up to September 1,
2014 were reviewed in the initial stage, without any other
limitations on the publication type and language. We also
hand-searched the reference lists of eligible studies and
relevant conference abstracts. This process was repeated
until no additional studies were found.
Selection criteria
Two authors independently reviewed and selected articles
according to the following inclusion criteria: (1) Included
studies should be randomized controlled trials. (2) Eligible
patients were diagnosed with head and neck cancers, and
underwent radiation therapy as primary or adjuvant therapy.
(3) Patients took pilocarpine daily during radiation therapy.
(4) Patients in the control group received placebo, or no
intervention for xerostomia prevention. (5) The sample size
of patients receiving pilocarpine should be larger than 10.
Data extraction
Two authors independently reviewed the included articles
and extracted data using a pre-established form, covering
information about author, publication year, study design,
country, sample size, tumor sites, exposed volume of sali-
vary glands, intervention regimen, major endpoints, and
duration of observation Q3. The completed forms were
checked by a third author. Any inconsistency was resolved
through discussion and consensus.
Assessment of risk of bias in included studies
The Cochrane Collaboration’s tool (Cochrane Handbook
version 5.1.0) for assessing risk of bias in randomized trials
was adopted in this systematic review (15). Two authors
independently evaluated the risk of bias of included trials in
6 domains. We also contacted corresponding authors for
further clarity of randomization, concealment, blinding
method, and incomplete outcome data. If available infor-
mation was insufﬁcient to eliminate a bias, we would deﬁne
it as “unclear risk” rather than “low risk.”
Data analysis
Outcome variables were extracted for meta-analysis. For
salivary ﬂow rates, clinician-rated xerostomia grades, and
patient-reported xerostomia scores, we calculated mean
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differences (MDs) with 95% conﬁdence intervals (CIs)
between groups during and after the course of radiation
therapy (months). Mean differences were based on the
ﬁxed-effect model, because the estimate of between-study
variance is poor when the number of studies is small (16).
The ﬁxed-effect meta-analysis provided the best pooled
intervention effect estimate (17). Heterogeneity was eval-
uated with the Pearson c2 test and I2 test. All assessments
and calculations were performed using Review Manage
(version 5.3; OxfordQ4 , United Kingdom) and SPSS Statistics
(version 22.0) (SPSS, Chicago, IL).
Results
Selection of trials
Of 495 reports initially identiﬁed (Fig. 1), 471 were
excluded by title and abstract. The remaining 24 reports
were screened at full-text level. Relevant references were
manually searched, and 2 additional reports were added.
According to the predeﬁned inclusion and exclusion
criteria, 8 reports of 6 clinical trials were included (18-26)
(Table 1).
Description of the included studies and data
analysis
All 6 trials in 8 articles were prospective trials. The trial by
Fisher et al (19)Q5 was conducted in multiple centers in the
United States, and the trial by Burlage et al (18) was
conducted in 2 medical centers in the Netherlands, whereas
the other included trials were single-centered.
The total number of patients was 369 in the pilocarpine
group, and 367 in the control group. The mean age of
patients was approximately 60 years in 5 trials (18-20,
22-26) Q6. However, in the trial by Haddad et al (21), the
mean age of patients was 43 years, possibly owing to its
different composition of tumors; most (76.9%) were naso-
pharyngeal carcinomas. The subtypes of tumors were re-
ported according to their sites in every trial. The
oropharynx, the oral cavity, and the larynx were the most
commonly involved tumor sites, respectively accounting
for 33.6%, 20.3%, and 19.5% (18-21, 23-26). More than
50% of the bilateral parotid glands received a dose of 50 Gy
in most of the trials. An exception was the trial by Burlage
et al (18): to study the inﬂuence of different exposed vol-
umes of parotid glands, they recruited patients with a range
of parotid volumes and divided them into 3 groups, which
had an irradiated volume of parotid gland of 25%-45%,
46%-75%, and >75%, respectively.
A dose of 5 mg pilocarpine per administration was
consistent in all the studies. Patients were instructed to take
pilocarpine either 3 times daily, or 4 times. Patients took
pilocarpine during radiation therapy and continued for
different periods ranging from 2 weeks to 3 months. The
period of follow-up varied from 5 weeks to 1 year after
treatment (20, 22).
Studied endpoints included objective, clinician-rated,
and patient-reported indicators evaluating the alleviation of
radiation-induced xerostomia. Objective data could be the
salivary ﬂow rate calculated as mL/min, including stimu-
lated and unstimulated salivary ﬂow rates. Clinician-rated
grades of xerostomia according to the known scales were
reviewed, such as the Late Effects of Normal Tissues
Subjective, Objective, Management, and Analytic (LENT
SOMA) scale, and the Radiation Therapy Oncology Group
Acute Xerostomia Toxicity scale (27-29). Patient-reported
xerostomia was measured using a visual analogue scale
or Likert scale when responding to xerostomia-related
495 of records retrieved
through database searching
2 additional records retrieved
from reference lists
471 records excluded
26 of full-text articles
assessed for eligibility
8 articles included in stystematic
review and meta-analysis
497 of records screened
by title and abstract
13: pilocarpine administrated after RT
18 of full-text articles excluded
1: consecutive allocation
1: subjects less than 10
1: integrated study of two published trials
2: retrospective study
Fig. 1. Selection process for studies included in the systematic review. Abbreviation: RT Z radiation therapy.
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questions, such as the 1-item questionnaire by Gornitsky in
2004, the 6-item questionnaire by Johnson in 1993, and the
12-item questionnaire by Burlage in 2008 (20, 30-32).
Because these questionnaires all focused on xerostomia and
the aspects evaluated were similar, we extracted mean
patient-reported scores, representing the overall xero-
stomia, at each time point. The scores were standardized on
a 0-100 scale for ﬁnal synthesis (32).
The impact of xerostomia on patients’ QoL was evalu-
ated through validated questionnaires, such as the
McMaster University Head and Neck Questionnaire, and
the University of Washington-Quality of Life Question-
naire. Finally, adverse effects of pilocarpine were qualita-
tively assessed by reviewing records in the included clinical
trials. Studies containing one or more of the above end-
points were included and thoroughly reviewed.
Risk of bias in included studies
The 6 included studies were all prospective, randomized
clinical trials. It was difﬁcult to gain information regarding
allocation concealment and eliminate the risk of selection
bias. In the trial by Fisher et al (19), eligible patients from
multiple centers were registered to a treatment arm by
Radiation Therapy Oncology Group headquarters, and pa-
tient factors were balanced by the headquarters other than
by institutions. Most of the other studies, though, neglected
to describe their methods of performing allocation.
Considering performance bias, in the trial by Nyarady et al
(23), the control group received neither pilocarpine nor
placebo, so double-blinding was violated. Unclear infor-
mation about the number of early dropouts was considered
to be bias-producing. Intention-to-treat analysis was
regarded as an ideal statistical method in such circum-
stances. In the study by Gornitsky et al (20), a missing data
replacement technique was used, using mean values from
corresponding groups. In the study by Fisher et al (19) the
schedule for data collection of the University of Washing-
ton Quality of Life Questionnaire at the completion of ra-
diation therapy was not carried out (Fig. 2).
Efﬁcacy and safety of concomitant pilocarpine for
radiation-induced xerostomia
Salivary ﬂow rate
Three included studies measured unstimulated salivary ﬂow
rate. Their data at each time point were synthesized to
calculate the MDs between groups. At baseline the
Table 1 Main characteristics of randomized, controlled trials included in the systematic review and meta-analysis of concomitant
pilocarpine for radiation-induced xerostomia
Study (year)
(reference)
N
(Pilo/Ctrl)
Patient characteristics
Pilocarpine
group
Control
group
Outcomes
Duration of
observationAge (y) Exposed volume Indicators Time points
Burlage
(2008) (18)
169 (85/84) 18-60: 54%
>60: 46%
Include 25% of
parotid gland to
a mean dose of
40.25 Gy
5 mg q.i.d.
continued for
14 d after RT
Placebo PFCP; LENT
SOMA; PRX:
12-item
Before RT, at
6 wk, 6 mo,
12 mo after RT
12 mo
Fisher
(2003) (19)
249 (124/125) 60 60-70 Gy to the
oral cavity and
oropharynx,
>50% of the
major salivary
gland to doses
>50 Gy
5 mg q.i.d.
continued for
3 mo
Placebo USF, SSF; RTOG;
UW-QOL
Before RT, at the
end of RT, at 3,
6 mo after
treatment
6 mo
Scarantino
(2006) (25)
Gornitsky
(2004) (20)
58 (29/29) 59.8 Include 2/3 of
all major and
minor salivary
glands 50 Gy
5 mg 5 times daily
during RT;
q.i.d. for 5 wk
after RT
Placebo USF, SSF; PRX:
1-item; QOL;
AEs
Before RT, at the
end of RT, 5 wk
after RT
5 wk
after RT
Haddad
(2002) (21)
60 (31/29) 43 Whole parotid
with a mean
dose of 58 Gy
5 mg t.i.d.
continued for
3 mo
Placebo PRX: 6-item;
LENT SOMA
6 mo after the end
of RT
6 mo
after RT
Nyarady
(2006) (23)
70 (35/35) 59 Total dose of
60 Gy
5 mg t.i.d.
continued for
12 wk
Pilocarpine
in the
last 6 wk
USF; PRX: 6-item Every second
week for 12 wk
12 wk
Warde
(2002) (26)
130 (65/65) 57 Include >50% of
both parotid
glands to doses
>50 Gy
5 mg t.i.d.
continued for
1 mo after RT
Placebo PRX: 6-item;
MU-HNRQ;
AEs
Baseline and
weekly during
RT, and 1, 3,
6 mo after RT
6 mo
after RT
Ringash
(2005) (24)
Abbreviations: AEsZ adverse effects of pilocarpine; LENT SOMAZ objective grades of the Late Effects of Normal Tissues Subjective, Objective,
Management and Analytic; MU-HNRQ Z McMaster University Head and Neck Questionnaire; PFCP Z stimulated parotid ﬂow rate complication
probability; PRXZ patient-rated xerostomia scoring [PRX (1-item) by Gornitsky in 2004; PRX (6-item) by Johnson in 1993; PRX (12-item) by Burlage
in 2008]; q.i.d. Z four times daily; QOL Z quality of life; RT Z radiation therapy; RTOG criteria Z Radiation Therapy Oncology Group acute
morbidity scoring criteria; SSF Z stimulated salivary ﬂow; t.i.d. Z three times daily; USF Z unstimulated salivary ﬂow; UW-QOL Z University of
Washington Quality of Life Questionnaire.
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unstimulated salivary ﬂow rates were similar between the
pilocarpine and control groups (MD 0.02 mL/min; 95%
CI -0.13, 0.09; PZ.68). During radiation therapy the
concomitant administration of pilocarpine increased the
amount of unstimulated saliva per minute. Immediately
after radiation therapy the unstimulated salivary ﬂow rate of
the pilocarpine group was signiﬁcantly increased (MD
0.28 mL/min; 95% CI 0.18, 0.37; P<.00001). The advan-
tageous effect of pilocarpine continued for 3 months after
radiation therapy; however, the increased rates declined
over time. At 5-6 weeks, the increase of unstimulated
salivary ﬂow rate was 0.15 mL/min (95% CI 0.07, 0.24;
PZ.0005), and at 3 months the increased rate was 0.10 mL/
min (95% CI 0.00, 0.20; PZ.04). By 6 months after radi-
ation therapy the difference between groups was insigniﬁ-
cant (MD 0.10 mL/min; 95% CI 0.02, 0.22; PZ.09)
(Fig. 3).
A signiﬁcant decrease in stimulated salivary ﬂow rate
after radiation therapy was observed in 2 trials. However,
no signiﬁcant difference was detected between arms (18,
20, 25).
Clinician-rated scoring of xerostomia
Two included studies measured the xerostomia grade using
the LENT SOMA scale. Available data were synthesized at
6 months. The severity of xerostomia was less in the
pilocarpine group (MD 0.41 points; 95% CI 0.65,
0.17; PZ.0008) (Fig. 4).
Patient-reported scoring of xerostomia
Four included studies provided patient-reported xerostomia
scores. Xerostomia was complained of during radiation
therapy and persisted in the following 12 months. At
baseline, xerostomia scores were similar between the
pilocarpine and control groups (MD 0.46; 95% CI 4.76,
3.84; PZ.83). After radiation therapy, patients in the
pilocarpine group did feel a little better than those in the
control group (MD 9.40; 95% CI 17.96, 0.83;
PZ.03). However, at 1-3 months after radiation therapy,
patients’ scorings of xerostomia were not signiﬁcantly
different. Thereafter at 6 months, the xerostomia scores in
the pilocarpine group were better than those in the control
group (MD 7.59; 95% CI 14.49, 0.69; PZ.03). At
12 months we included only 1 trial, by Burlage et al (18),
indicating the favorable effect of pilocarpine (MD 16.50;
95% CI 29.07, 3.93; PZ.01) (8, 13) Q7(Fig. 5).
Quality of life
Two trials adopted validated questionnaires to assess QoL.
XXXX Q8et al used the McMaster University Head and Neck
questionnaire, revealing no difference between the pilo-
carpine and the placebo groups during or after radiation
therapy. The QoL declined signiﬁcantly during radiation
therapy but gradually returned to the baseline score by
6 months after treatment. The patient-reported xerostomia,
in contrast with the QoL, worsened and persisted in both
arms (24, 26). Fisher et al used the University of Wash-
ington Head and Neck Symptom Scale questionnaire in
their trial. Even though the unstimulated saliva increased in
the pilocarpine group, no improvement in QoL during the
follow-up 6 months was reported (19, 25).
Adverse effects of pilocarpine
Several included articles reported adverse effects of pilo-
carpine, including nausea, lacrimation, sweating, rhinitis,
mild headache, and urinary frequency (21, 23, 26). The
observed adverse effects were usually mild and tolerable.
Meta-analysis was not performed because included studies
failed to report quantiﬁable outcome measures. On the
basis of the original report from the largest trial, no sta-
tistical difference was reported between the pilocarpine
group and the placebo group (25). Only 1 patient receiving
pilocarpine discontinued the medication because of exces-
sive sweating (18).
Discussion
The efﬁcacy of pilocarpine on the treatment of radiation-
induced xerostomia has been studied since the 1990s (31).
The morbidity of radiation-induced xerostomia is better
avoided than treated (21). Thus, the preventive effect of
Burlage 2008
Fisher 2003
Gornitsky 2004
Haddad 2002
Nyarady 2006
Warde 2002
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Fig. 2. Risk of bias summary review authors’ judgments
about each risk of bias item for each included study.
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pilocarpine deserved attention through high-quality ran-
domized, controlled trials. We searched online databases
and identiﬁed 6 randomized, controlled trials in a meta-
analysis, addressing this question. The results showed
that concomitant administration of pilocarpine during ra-
diation could increase the unstimulated salivary ﬂow rate
over a period of 3-6 months after treatment, alleviate the
severity of clinician-rated xerostomia grade up to 6 months
after treatment, and possibly relieve patient-reported
xerostomia during the time frame of 6-12 months after
treatment.
Our meta-analysis demonstrated that preventive pilo-
carpine could increase the unstimulated salivary ﬂow rate,
but the advantageous effect continued for only a period of
3-6 months. In the ﬁrst 6 months, concomitant pilocarpine
exhibited a favorable effect, but over time the relative
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Fig. 3. Unstimulated salivary ﬂow rates during and after course of radiation therapy. Depicts mean differences between the
pilocarpine group and the control group. Abbreviation: CI Z conﬁdence interval.
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Fig. 4. Mean difference of clinician-rated xerostomia grades between the pilocarpine group and the control group at
6 months. Abbreviation: CI Z conﬁdence interval.
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increased unstimulated salivary ﬂow rate kept descending.
This phenomenon could be due to different mechanisms of
salivary gland damage induced by radiation in different
time phases. In the early phase after radiation, the main
mechanism of xerostomia is attributable to plasma mem-
brane damage, which could be prevented by pilocarpine or
other speciﬁc receptor agonists (33). An in vivo study by
Burlage et al (34) discovered that pilocarpine could in-
crease proliferation of undamaged cells in the early phase
when there was a sufﬁcient number of remaining progenitor
cells. In the late phase (approximately 120 days later),
salivary ﬂow rate further deteriorated, because of acinar
cell apoptosis and the damaged extracellular environment
(35). Thus the concomitant application of pilocarpine was
hypothesized to be effective only in the early phase of
radiation-induced xerostomia. The protective effect may
also have accounted for the decreased clinician-rated
xerostomia grade at 6 months.
Although the unstimulated saliva ﬂow improved in the
pilocarpine group, pilocarpine had no effect on stimulated
salivary ﬂow rate. It was suggested that the parotid glands,
which produce stimulated saliva, might be more vulnerable
to radiation (36), and the recoverability of the parotid
glands after radiation might be weaker than the mucous
salivary glands. However, the assumption was rejected by
subsequent studies (37, 38), which showed that the func-
tional loss was quite comparable between the parotid and
submandibular glands (37). The inconsistent response to
pilocarpine between the unstimulated and stimulated saliva
might result from the sialagogic effect of pilocarpine. The
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Fig. 5. Subjective xerostomia scores during and after course of radiation therapy. Depicts mean differences between the
pilocarpine group and the control group. Abbreviation: CI Z conﬁdence interval.
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daily administration of pilocarpine was presumed to keep
the salivary glands in the stimulated condition. When
secreting at a maximum rate, no more saliva could be
secreted even with another stimulus, hence the stimulated
saliva showed no signiﬁcant change. Our ﬁnding was
similar to those from the study by Wasserman et al (39),
who observed a signiﬁcant increase in unstimulated saliva
production but found no difference in stimulated saliva ﬂow
in patients receiving the radioprotective agent of
amifostine.
With respect to the patient-reported xerostomia, pilo-
carpine alleviated symptoms at 6 months, and possibly at
12 months (although only 1 study provided 12-month
data). Considering the minimally important difference of
5-10% improvement required to prove the clinical value
of pilocarpine, the patient-reported xerostomia at
6 months was of borderline signiﬁcance (40). The
discrepancy between patient-reported xerostomia and
unstimulated saliva might be attributed to the varied and
uncontrolled radiation doses of the submandibular glands
and minor salivary glands, which would affect mucin
secretion and was a critical factor for the patient-reported
xerostomia scores (11, 41-43).
Two included trials found concomitant administration of
pilocarpine during radiation therapy could not signiﬁcantly
improve QoL compared with the placebo group (19, 24).
One potential reason may be that the adopted QoL ques-
tionnaire did not adequately measure xerostomia (24, 44).
Fisher et al (19) explained that the ameliorated xerostomia
was not perceived to be ideal, negatively affecting patients’
self-appraisal of their status. Another possibility is that the
radiation-induced mucositis produces similar dysfunctions
as xerostomia, and thus reduces the QoL (19). Jellema et al
(45) evaluated patients’ xerostomia and QoL using the
Radiation Therapy Oncology Group acute morbidity
scoring criteria and the European Organization for
Research and Treatment of Cancer QLC-C30. They found a
signiﬁcant impact of clinician-rated xerostomia on QoL,
and the effect size increased over time even as the inci-
dence of xerostomia decreased. The inconsistency in
different studies indicates that the correlation between
saliva ﬂow, clinician- or patient-rated xerostomia, and QoL
is complicated and should be further clariﬁed in future
studies.
The effect of pilocarpine on increasing unstimulated
saliva needs to be highlighted even in the IMRT era. In-
tensity modulated radiation therapy is most useful in
sparing the parotid glands (46) and can be combined with
pilocarpine to obtain a complementary outcome. Even with
IMRT, xerostomia is still a common side effect (13). Pa-
tients with N2c lymph node disease will often have mar-
ginal sparing of bilateral parotid glands, and large tumors
of base of tongue may preclude submandibular glands
sparing. Such circumstances will cause unavoidable
radiation-induced xerostomia, which underlines the role of
pilocarpine. Furthermore, IMRT produces long-term relief
of xerostomia (8), whereas pilocarpine has more of a short-
term beneﬁt. Therefore, the combination of pilocarpine and
IMRT is promising in preventing xerostomia and warrants
further investigation.
Certain limitations in this systematic review should be
taken into account. First, the number of included studies is
limited, which underlines the necessity to combine avail-
able evidence for clinical guidance. Relevant outcomes
should be interpreted carefully, and further high-quality
trials are proposed. Second, the long-term efﬁcacy of
pilocarpine has to be further investigated, because no study
in our analysis tracked outcomes beyond 12 months. Last,
the adopted patient-reported or clinician-rated instruments
for grading xerostomia, or the QoL questionnaires, are
diverse, bringing about difﬁculty in comparing studies. A
guideline concerning the design and implementation of
future clinical trials should be recommended.
Conclusions
The concomitant administration of pilocarpine during ra-
diation can increase unstimulated salivary ﬂow rate and
reduce clinician-rated xerostomia grade after radiation. It
may also relieve patients’ xerostomia at 6 months, and
possibly at 12 months. However, it has no effects on
stimulated salivary ﬂow rate. More high-quality trials are
needed, with standardized outcome measures including the
normalized measurement of salivary ﬂow, clinician-rated
xerostomia grade, patient-reported xerostomia, and a
specialized QoL questionnaire.
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